In 2024, Johnson & Johnson's sales in the United States came to over ** billion U.S. dollars. Thus, the largest part of the company’s revenue was generated in the United States. Europe is the company's second most yielding region, with some ** billion U.S. dollars in sales. Johnson & Johnson is a U.S.-based multinational company, specializing in pharmaceuticals and medical technology. The company is headquartered in New Brunswick, New Jersey. Johnson & Johnson’s global positioning Johnson & Johnson was among the top pharmaceutical companies globally in recent years. Based on prescription sales and research and development spending, Johnson & Johnson was ranked first in prescription sales and second in spending on research and development. In terms of the research and development pipeline, Johnson & Johnson ranked among the top seven pharmaceutical companies worldwide as of 2024. Research and development at Johnson & Johnson Johnson & Johnson’s expenditures on research and development, like their revenue, has been increasing recently. When viewed as a percentage of revenue, research and development spending has only increased significantly in 2024, to over ** billion U.S. dollars.

In fiscal year 2024, Johnson & Johnson's revenue by geographical region are as follows: Asia-Pacific, Africa: $13.59 B, Europe: $20.21 B, UNITED STATES: $50.30 B, Western Hemisphere, excluding U.S.: $4.71 B.

This statistic shows the total revenue of Johnson & Johnson worldwide from 2012 to 2024. Johnson & Johnson is a multinational company, specialized on pharmaceuticals, medical devices and consumer goods. The company is headquartered in New Brunswick, New Jersey. In 2018, Johnson & Johnson's global revenue is estimated to amount to about 78.27 billion U.S. dollars.

In fiscal year 2024, Johnson & Johnson's revenue by segment (products & services) are as follows: Innovative Medicine: $56.96 B, MedTech: $31.86 B.

This statistic shows the revenue of Johnson & Johnson worldwide from 2018 to 2024, by segment. Johnson & Johnson is a multi-national company, specialized on pharmaceuticals, medical devices and consumer goods. The company is headquartered in New Brunswick, New Jersey. In 2018, the consumer healthcare segment of Johnson & Johnson is estimated to generate 3.33 billion U.S. dollars of the company's global revenue.

Introduction

Johnson & Johnson Statistics: Johnson & Johnson (J&J) is a global leader in healthcare, offering a wide range of products in pharmaceuticals, medical devices, and consumer health. In 2024, it will continue to maintain its position as a powerhouse in the healthcare sector, driven by innovation, strategic acquisitions, and a strong commitment to sustainability. This article has covered all essential analyses of the platform's current trends from different insights and will guide you accordingly.

In 2024, Johnson & Johnson’s net earnings were estimated to be about 14 billion U.S. dollars. This is a significant decrease compared to the previous year, when net earnings stood at about 35 billion U.S. dollars. Johnson & Johnson’s revenue overview Johnson & Johnson is a U.S.-based multinational company that is headquartered in New Brunswick, New Jersey, in the United States. The company’s largest business segment is their pharmaceutical segment, but the company also operates in medical devices and diagnostics. Regionally, the United States is responsible for the largest proportion of Johnson & Johnson’s sales, followed by Europe. Johnson & Johnson’s global R&D positioning Johnson & Johnson has been ranked second among global pharmaceutical companies based on their dollar amount spent on research and development in 2023. Johnson & Johnson is ranked among the top 10 pharmaceutical companies based on the number of originated drugs. Similarly, Johnson & Johnson is ranked among the top seven pharmaceutical companies based on the number of drugs in development as of 2024.

In 2018, Johnson & Johnson generated over 12 billion U.S. dollars in revenue through immunology products. Revenue from this product category is projected to decrease in the coming years, while earnings from the oncology category are set to increase.

Johnson & Johnson’s total revenue

Johnson & Johnson’s global revenue came to some 82 billion U.S. dollars in 2019 – although this is the total revenue from all three of the company’s segments. Over the past decade, the company’s total revenue numbers have increased by almost 22 percent. The multinational, headquartered in New Jersey, earns roughly half of that revenue in its home market: in 2018, J&J generated close to 42 billion U.S. dollars in the United States. A total of approximately 15 billion U.S. dollars were made in the African and Asian Pacific regions that year.

J&J WORKFORCE

In 2017, J&J’s workforce count had, for the first time, reached and exceeded the 130 thousand mark. In 2018 specifically, just over 135 thousand people worked for Johnson & Johnson. These employees are active in various areas in over 60 countries worldwide: from pharmaceutical R&D to manufacturing and sales.

Johnson & Johnson’s medtech (medical devices and diagnostics) segment earned about **** billion U.S. dollars through its surgery franchise in 2024. Orthopedics was the second-largest franchise, generating roughly *** billion U.S. dollars that year. J&J’s revenue In 2024, Johnson & Johnson’s global revenue amounted to some ** billion U.S. dollars, which was an increase of around ***** billion U.S. dollars compared to 2023. During 2023, the consumer health business of the company was moved in a spin-off. J&J currently has two major segments: Innovative Medicine and Medtech. In 2024, over ***billion U.S. dollars were generated through the medtech division. That was roughly ** percent of the company’s total global revenue. Over the years, the multinational company with its various segments generated more than half of its revenues in the United States, making it the company’s main market. In 2024, around **** billion U.S. dollars were generated in Europe.

J&J reported $21.89B in Sales Revenues for its fiscal quarter ending in March of 2025. Data for J&J | JNJ - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last July in 2025.

JR: Same-Store Sales: FS: Finish Line data was reported at -7.900 % in Jan 2018. This records a decrease from the previous number of 0.800 % for Oct 2017. JR: Same-Store Sales: FS: Finish Line data is updated quarterly, averaging 3.600 % from Jul 2011 (Median) to Jan 2018, with 27 observations. The data reached an all-time high of 12.300 % in Oct 2012 and a record low of -7.900 % in Jan 2018. JR: Same-Store Sales: FS: Finish Line data remains active status in CEIC and is reported by Redbook Research Inc.. The data is categorized under Global Database’s USA – Table US.H014: Johnson Redbook Same-Store Sales Index: Quarterly: YoY%.

United States Johnson Redbook: Total Sales Base data was reported at 12.440 USD bn in Jan 2019. This records a decrease from the previous number of 12.500 USD bn for Dec 2018. United States Johnson Redbook: Total Sales Base data is updated monthly, averaging 17.461 USD bn from Jan 1998 (Median) to Jan 2019, with 253 observations. The data reached an all-time high of 19.904 USD bn in Jan 2002 and a record low of 12.330 USD bn in Nov 2017. United States Johnson Redbook: Total Sales Base data remains active status in CEIC and is reported by Redbook Research Inc.. The data is categorized under Global Database’s United States – Table US.H012: Johnson Redbook Index: Monthly.

J&J reported 138.1K in Employees for its fiscal year ending in December of 2024. Data for J&J | JNJ - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last July in 2025.

United States JR: Same-Store Sales: OS: The Container Store data was reported at 2.700 % in Apr 2018. This records an increase from the previous number of -0.200 % for Jan 2018. United States JR: Same-Store Sales: OS: The Container Store data is updated quarterly, averaging -0.300 % from Jan 2014 (Median) to Apr 2018, with 18 observations. The data reached an all-time high of 4.700 % in Jan 2014 and a record low of -4.200 % in Oct 2016. United States JR: Same-Store Sales: OS: The Container Store data remains active status in CEIC and is reported by Redbook Research Inc.. The data is categorized under Global Database’s USA – Table US.H012: Johnson Redbook Same-Store Sales Index: Quarterly: YoY%.

United States JR: Same-Store Sales: AS: American Eagle Outfitters data was reported at 9.000 % in Jul 2018. This stayed constant from the previous number of 9.000 % for Apr 2018. United States JR: Same-Store Sales: AS: American Eagle Outfitters data is updated quarterly, averaging 3.000 % from Jan 2011 (Median) to Jul 2018, with 31 observations. The data reached an all-time high of 17.000 % in Apr 2012 and a record low of -10.000 % in Apr 2014. United States JR: Same-Store Sales: AS: American Eagle Outfitters data remains active status in CEIC and is reported by Redbook Research Inc.. The data is categorized under Global Database’s United States – Table US.H014: Johnson Redbook Same-Store Sales Index: Quarterly: YoY%.

This statistic depicts the net sales of Mead Johnson Nutrition Company worldwide in 2016, by region. In that year, Mead Johnson generated net sales of about 1.86 billion U.S. dollars in Asia. Mead Johnson is one of the largest manufacturers in pediatric nutrition and owns the brand family Enfa, including Enfamil infant formula.

The global Roxithromycin market is experiencing robust growth, driven by increasing prevalence of bacterial infections susceptible to this macrolide antibiotic. While precise market size figures for 2025 are unavailable, considering similar antibiotic markets and reported CAGRs for related drugs, a reasonable estimate for the 2025 market size would be around $500 million. Assuming a conservative Compound Annual Growth Rate (CAGR) of 5% for the forecast period (2025-2033), the market is projected to reach approximately $780 million by 2033. This growth is fueled by several factors, including the rise in antibiotic-resistant bacterial strains, which necessitates the use of effective alternative antibiotics like Roxithromycin, the increasing incidence of respiratory infections and skin infections globally, and expanding access to healthcare in developing economies. However, the market faces certain restraints including the potential for adverse effects, the development and increased use of newer antibiotics with broader-spectrum activity, and stringent regulatory pathways for drug approvals. The market is segmented based on various factors including dosage form, route of administration, and geographic location. Key players in the Roxithromycin market include established pharmaceutical companies such as Hetero Healthcare, Johnson & Johnson, and Bayer AG, as well as specialized manufacturers like Finecure Pharmaceuticals and Zhejiang Zhenyuan Pharmaceutical. The competitive landscape is marked by a blend of large multinational corporations and smaller specialized firms. The strategic initiatives of market players, including mergers, acquisitions, and new product development, will play a crucial role in shaping market dynamics over the forecast period. Geographic expansion into emerging markets and efforts to increase product awareness are vital for growth. Focusing on the development of novel drug delivery systems to improve efficacy and reduce side effects, along with strategic partnerships and collaborations will be key for companies to maintain a competitive edge in the dynamic Roxithromycin market. The market segmentation across various regions will likely show significant variations in growth rates, reflecting differences in healthcare infrastructure, disease prevalence, and regulatory environments.

Graph and download economic data for All Employees: Retail Trade in Johnson City, TN (MSA) (SMU47277404200000001SA) from Jan 1990 to May 2025 about Johnson City, TN, retail trade, sales, retail, employment, and USA.

JR: Same-Store Sales: FS: YoY: Median data was reported at 4.400 % in Jul 2018. This records an increase from the previous number of 0.250 % for Apr 2018. JR: Same-Store Sales: FS: YoY: Median data is updated quarterly, averaging 2.300 % from Jul 2011 (Median) to Jul 2018, with 29 observations. The data reached an all-time high of 11.600 % in Jul 2011 and a record low of -1.100 % in Apr 2017. JR: Same-Store Sales: FS: YoY: Median data remains active status in CEIC and is reported by Redbook Research Inc.. The data is categorized under Global Database’s USA – Table US.H014: Johnson Redbook Same-Store Sales Index: Quarterly: YoY%.

This dataset tracks annual average revenue per student from 2004 to 2021 for Timothy L Johnson Academy School District